Massachusetts State Resource Center

Massachusetts Trawler

Our Mission

ALF promotes education, advocacy, support services and research for the prevention, treatment and cure of liver disease. ALF Mid-Atlantic provides a wide variety of these services including information and referral, education programs, support groups, exciting fundraising events, and an array of volunteer opportunities.

For help with issues related to liver disease, please contact our Help Center by using the Live Chat feature at the bottom of your browser window or call us at (800) 465-4837 Monday through Friday 9 am to 5 pm Eastern Time or by email at

COVID-19 Information on the Outbreak of COVID-19

Support Groups

Support groups provide a place for individuals affected by a similar condition or circumstance to provide and receive support and share their experiences.

Not all support groups are facilitated by an American Liver Foundation volunteer. Some support groups are facilitated by 3rd party organizations and individuals in this region. Some support groups may no longer be active and have not informed us; if you are aware of additional support groups in New England or groups which no longer meet, please e-mail us to let us know.


Anonymous Hepatitis C Support Group

COPE Center
81 Pleasant Street
Brockton, MA

Meets: Last Tuesday of the month, 7:00pm-8:30pm
Phone: (508) 583-3405


C is for Cure: Hepatitis C Support Group

Father Mychal Judge Recovery Center
St. Anthony Shrine
100 Arch Street
Boston, MA 02110

This is an American Liver Foundation sponsored Support Group providing answers to questions about testing, treatment, and where to turn for help.

Meets: Last Wednesday of the Month at 5:30 p.m.
Phone: 781-526-3679

Contact Anthony for more information.


Hepatitis C & Liver Disease Support Group

Lahey Hospital and Medical Center
41 Mall Road
4 West Conference Room
Burlington, MA

This group is open to pre and post-transplant patients, family, and caregivers as well. Please note, there is no group held in August.

Meets: 1st Wednesday, 6:00 p.m. – 7:30 p.m
Contact: Kimberly Ricciardone


Hepatitis C Support Group

AIDS Action Committee
359 Green Street
Cambridge, MA 02139

Lunch is offered during this support group. Attendees are invited to arrive at 12:30 for lunch. The meeting begins at 1 pm.

Meets: 1st Wednesday of the month, 1-2:30
Phone: 617-599-0225

Contact Luis (AIDS Action Committee) for more information.


Hepatitis C Support Group

North Shore Health Project
67 Middle Street
Gloucester, MA 02930

Meets: 2nd Saturday of month, 10-11:30am
Phone: (978) 283-0101

Contact Jason for more information.

Clinical Trials

Find a Clinical Trial anywhere…

Participating in a clinical trial is a great way to contribute to curing, preventing and treating liver disease and its complications. Start your search here to find clinical trials that need people like you.


A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children

Boston Children’s Hospital

  • All genotypes
  • Expect enrollment to start with 12-17 year olds by late winter/early spring 2017

Contact Courtney Glavin for more information.

Phone: 617-355-8350

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects with Genotype

Boston Children’s Hospital

  • All genotypes
  • Expect enrollment with 12/17 year olds by late winter/early spring 2017

Contact Denis Nguyen for more information.

Phone: 617-355-0530

An Open-Label, Multicenter, Study to Evaluate the Pharmacokinetics, Safety and Efficacy of OBV, PTV, RTV with or without DSV and with or without RBV i

Boston Children’s Hospital

  • Currently enrolling patients 9-11yo
  • Expect to enroll 8-10yo by spring/summer 2017

Contact Denis Nguyen for more information.

Phone: 617-355-0530

Phone: 617-724-3836

Massachusetts General Hospital

MGH has a few in the pipeline that they anticipate to be starting in the next 3-4 months (mainly NASH and HCV). In terms of MGH trials – the is a great contact to give out if people are just looking to hear more about what’s available, etc.

Intercept – drug Obeticholic Acid ( Identifier: NCT02548351)

Population: NASH + Fibrosis stage 1-3

Study Phase: 3

Treatment period: up to 5 years (interim analysis at 18 months)

Randomization: 1:1:1 (placebo/10mg/25mg)

* Genfit – drug Elafibranor

Population: NASH + Fibrosis (stage 1-4)

Treatment period: 72 weeks with long term treatment rollover (up to 4 additional years)

Study Phase: 3

Randomization: 2:1 (120mcg/placebo)

Conatus12 – drug Emricasan ( Identifier: NCT02686762)

Population: NASH + Fibrosis stage 1-3

Treatment period: 72 weeks + 4 weeks follow-up

Study Phase: 2

Randomization: 1:1:1 (placebo/5mg/50mg)

Novartis – drug LJN452 ( Identifier: NCT02855164)

Population: NASH + Fibrosis (stage 1-3)

Treatment period: 12 weeks

Study Phase: 2

Randomization: Part A: 1:1:1:1:1 (10mg/30mg/60mg/90mg/placebo)

NASH Cirrhosis

Conatus14 – Emricasan ( Identifier: NCT02960204)

Population: NASH + Cirrhosis + Severe Portal Hypertension (HVPG > 12)

Treatment period: 24 weeks

Study Phase: 2

Randomization: 1:1:1:1 (placebo/5mg/25mg/50mg)


Gilead – drug Harvoni ( Identifier: NCT02503735)

Population: Chronic Kidney Disease + HCV

Treatment period: 12 weeks

Study Phase: 4

Randomization: open label (no placebo)

AbbVie – drug Viekira Pak ( Identifier: NCT02946034)

Population: Chronic Kidney Disease + HCV

Treatment period: 12 weeks

Study Phase: 4

Randomization: open label (no placebo)

Contact (MGH Liver Research Group) for more information.

Phone: 617-724-3836


UMass Memorial Medical Center

University of Massachusetts Medical School
55 Lake Avenue North HA.382
Worcester, MA 01655-0002 USA

Severe Alcoholic Hepatitis

* Gilead Sciences: ASK1 Inhibitor + prednisolone vs prednisolone alone

* NIAAA: Anakinra/Pentoxyfilline/Zinc (has treatment as well as observational arms)

NASH (non-cirrhosis)

* Intercept: obetacholic acid

* Genfit: elafibranor

* 2 additional studies for NASH expected to open within the next few weeks.


* U of Florida/U of NC Chapel Hill: Longitudinal, observational study with patients being treated for approved HCV

Contact Monique Rinner, RN MBA, Research Nurse Coordinator (Department of Medicine, Division of Gastroenterology) for more information.

Phone: 774 442-1982

Related Links

Diseases of the Liver

Government Organizations

Liver Disease Diets

Liver Transplant

Medical Terminology

Patient Organizations

Professional Organizations

Progression of Liver Disease

Student Resources

In addition to the resources listed above in your state or district, ALF provides these resources that are available no matter where you are. Explore them now…

Last updated on September 20th, 2022 at 12:28 pm

cross linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram